An improved trace analysis for N-nitrosoureas from biological media

Area of Science:

• Pharmacology
• Analytical Chemistry
• Oncology

Background:

• 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) is a critical chemotherapeutic agent used for various cancers.
• Accurate and rapid quantification of BCNU in biological matrices is essential for therapeutic drug monitoring and pharmacokinetic studies.
• Existing analytical methods may lack the sensitivity, speed, or cost-effectiveness required for routine clinical application.

Purpose of the Study:

• To develop and validate a rapid, convenient, and cost-effective High-Performance Liquid Chromatography with Ultraviolet detection (HPLC-UV) method for quantifying 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU) in biological samples.
• To compare the detection limits of HPLC-UV with other methods like High-Performance Liquid Chromatography with Electrochemical detection (HPLC-EC) and the Griess Test.
• To assess the utility of the developed method for determining BCNU distribution and elimination kinetics in blood.

Main Methods:

• High-Performance Liquid Chromatography with Ultraviolet detection (HPLC-UV) was employed for BCNU analysis.
• The method was applied to various biological media, including patient and control blood samples.
• Detection limits were compared across HPLC-UV, HPLC-EC, and the Griess Test.

Main Results:

• The HPLC-UV method demonstrated the ability to quantify BCNU at trace levels relevant to clinical importance.
• The method proved to be rapid, with complete analysis of individual blood samples achieved in under 30 minutes from sampling.
• Comparisons indicated the effectiveness of HPLC-UV for BCNU detection in biological samples.

Conclusions:

• HPLC-UV offers a practical and efficient approach for the rapid, inexpensive determination of BCNU in biological fluids.
• The developed method facilitates quick assessment of BCNU pharmacokinetics, including its distribution and disappearance from blood.
• This analytical strategy supports improved therapeutic drug monitoring for BCNU-treated patients.